SCHEMBL30795913

SCHEMBL30795913

CCCCCn1c(=O)c(C(=O)NCc2cccc(F)c2)c(C)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.47
POLB P06746 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
USP2 O75604 2/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 2/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
S1PR3 Q99500 1/20 0.45
XBP1 P17861 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
GLS O94925 1/20 0.43
MAPT P10636 2/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29819 1.00 CNR2 (0.47) CNR2POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL30795727 0.97 POLB (0.50) CNR2POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL29667 0.97 POLB (0.50) CNR2POLBSMN1; SMN2KDM4EALDH1A1
SCHEMBL30795738 0.94 S1PR3 (0.47) POLBSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL715295 0.94 S1PR3 (0.47) POLBSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL30794729 0.91 S1PR3 (0.45) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL29862 0.91 S1PR3 (0.45) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL29002 0.91 S1PR3 (0.45) S1PR3RXFP1GLSMAPTCCR1
SCHEMBL30795875 0.91 S1PR3 (0.45) S1PR3RXFP1GLSMAPTCCR1
SCHEMBL30795805 0.90 S1PR3 (0.50) KDM4EALDH1A1LMNAHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed